xMedica

NCT04153292ClinicalTrials.gov

The ENCIRCLE Trial

SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects…

Interventistico900 partecipanti ricercati68 centri6 paesi

Categorie

Cardiovascolare100%

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2019-11-06; recorded start 2020-11-12
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are not randomly assignedAllocation is recorded as non-randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Open label (no blinding)Masking is recorded as none (open label)
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 47 other studies in this databaseCounted from the lead sponsor named in the record (Edwards Lifesciences)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourMODERATE

A moderately rigorous design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Non-randomised allocation

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 68 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 900 participants (target), run at 68 sites, across 6 countries.

How this score is built
  • Enrolment29/40

    900 participants (target)

  • Site count21/25

    68 sites

  • Country count12/15

    6 countries

  • Planned duration10/10

    Planned over about 125 months

  • Sponsor scale6/10

    Edwards Lifesciences has led 47 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

This is a prospective single-arm, multicenter study.

Patologie

  • Mitral Regurgitation
  • Mitral Valve Insufficiency

Idoneità

SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: 1. 18 years of age or older 2. MR ≥ 3+ 3. NYHA functional class ≥ II 4. Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations. 5. Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment. 6. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. Exclusion Criteria: 1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve 2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve 3. Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation 4. Left ventricular ejection fraction \<25% 5. Severe right ventricular dysfunction 6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months 7. History of heart transplant 8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation 9. Active bacterial endocarditis within 180 days of the procedure 10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure 11. Myocardial infarction within 30 days of the procedure 12. Clinically significant untreated coronary artery disease requiring revascularization 13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure 14. Stroke or transient ischemic attack within 90 days of the procedure 15. Irreversible, severe pulmonary hypertension 16. Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic outpatient oral steroid use 17. Renal insufficiency or receiving renal replacement therapy 18. Liver disease 19. Planned surgery within the next 12 months 20. Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure 21. Active infection requiring current antibiotic therapy 22. Active SARS-CoV-2 infection (Coronavirus-19 \[COVID-19\]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments 23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states 24. Refusal of blood products 25. Female who is pregnant or lactating 26. Estimated life expectancy \<12 months due to non-cardiac conditions 27. Participating in another investigational drug or device study that has not reached its primary endpoint 28. Subject considered to be part of a vulnerable population

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Tipo di studioInterventistico
FaseNon applicabile
AssegnazioneNon randomizzata
Modello di interventoSINGLE_GROUP
Finalità principaleTREATMENT
MascheramentoNONE (0)
Arruolamento900 partecipanti ricercati

Sponsor e collaboratori

  • Edwards Lifesciences Sponsor

Bracci e interventi

  • TMVR - Main CohortEXPERIMENTAL

    Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).

  • TMVR - Failed TEER RegistryEXPERIMENTAL

    Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.

  • TMVR - MAC RegistryEXPERIMENTAL

    Subjects with mitral annular calcification (MAC) will have TMVR.

Interventi

  • Dispositivo SAPIEN M3 valve and dock

    During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

Esiti misurati

  1. Esito primario

    Non-hierarchical composite of death and heart failure rehospitalization

    Number of subjects with death and/or heart failure rehospitalization

    Orizzonte temporale 1 year

  2. Esito secondario

    Improvement in NYHA functional class compared to baseline

    New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.

    Orizzonte temporale 1 year

  3. Esito secondario

    Improvement in KCCQ Overall Score compared to baseline

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Orizzonte temporale 1 year

  4. Esito secondario

    Improvement in MR compared to baseline

    Number of subjects with improved MR compared to baseline

    Orizzonte temporale 1 year

  5. Esito secondario

    Decrease in LVEDVi compared to baseline

    Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline

    Orizzonte temporale 1 year

Date

Data di inizio12 novembre 2020 (effettiva)
Conclusione primaria28 febbraio 2027 (stimata)
Conclusione28 febbraio 2031 (stimata)
Prima pubblicazione6 novembre 2019 (effettiva)
Ultimo aggiornamento25 febbraio 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltafebbraio 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

3 centri stanno reclutando

Australia

StrutturaCittàStato o regioneStato
Royal Prince Alfred HospitalCamperdownAttivo, non in reclutamento
The Prince Charles HospitalChermsideQueenslandAttivo, non in reclutamento

Canada

StrutturaCittàStato o regioneStato
Laval UniversityQuébecQuebecIn reclutamento
St. Michael'sTorontoIn reclutamento
St. PaulsVancouverIn reclutamento

Israel

StrutturaCittàStato o regioneStato
Shaare Zedek Medical CenterJerusalemRitirato
Rabin Medical CenterPetah TikvaAttivo, non in reclutamento
Sheba Medical CenterRamat GanRitirato

Netherlands

StrutturaCittàStato o regioneStato
Leiden University Medical CenterLeidenAttivo, non in reclutamento
Rotterdam Erasmus MCRotterdamAttivo, non in reclutamento

United Kingdom

StrutturaCittàStato o regioneStato
Saint Thomas HospitalLondonAttivo, non in reclutamento
Saint Bartholomew's Medical CenterLondonAttivo, non in reclutamento

United States

StrutturaCittàStato o regioneStato
Piedmont HealthcareAtlantaGeorgiaAttivo, non in reclutamento
Emory UniversityAtlantaGeorgiaAttivo, non in reclutamento
Austin HeartAustinTexasAttivo, non in reclutamento
Medstar Union Memorial HospitalBaltimoreMarylandAttivo, non in reclutamento
Our Lady of the Lake Regional Medical CenterBaton RougeLouisianaAttivo, non in reclutamento
Brigham & Women'sBostonMassachusettsRitirato
Massachusetts General HospitalBostonMassachusettsAttivo, non in reclutamento
University of BuffaloBuffaloNew YorkAttivo, non in reclutamento
Novant Health and Vascular InstituteCharlotteNorth CarolinaAttivo, non in reclutamento
Carolinas Medical CenterCharlotteNorth CarolinaRitirato
Rush University Medical CenterChicagoIllinoisRitirato
The Christ HospitalCincinnatiOhioAttivo, non in reclutamento
Cleveland Clinic FoundationClevelandOhioAttivo, non in reclutamento
Mount Carmel East HospitalColumbusOhioAttivo, non in reclutamento
Delray Medical CenterDelray BeachFloridaRitirato
Henry FordDetroitMichiganAttivo, non in reclutamento
Cardiac & Vascular Institute FoundationGainesvilleFloridaAttivo, non in reclutamento
Northshore University Health SystemGlenviewIllinoisAttivo, non in reclutamento
UT Memorial HermannHoustonTexasAttivo, non in reclutamento
HCA Houston Healthcare Medical (SCRI)HoustonTexasAttivo, non in reclutamento
Heart Center HospitalHuntsvilleAlabamaAttivo, non in reclutamento
St. Vincent Heart Center of IndianaIndianapolisIndianaRitirato
Ascension St. Vincent's HospitalJacksonvilleFloridaAttivo, non in reclutamento
University of KansasKansas CityKansasAttivo, non in reclutamento
Saint Luke's Kansas CityKansas CityMissouriAttivo, non in reclutamento
Scripps HealthLa JollaCaliforniaAttivo, non in reclutamento
Dartmouth-Hitchcock Medical CenterLebanonNew HampshireAttivo, non in reclutamento
Good Samaritan HospitalLos AngelesCaliforniaAttivo, non in reclutamento
Kaiser Sunset LALos AngelesCaliforniaAttivo, non in reclutamento
Cedars-Sinai Medical CenterLos AngelesCaliforniaAttivo, non in reclutamento
UC Health Northern Colorado (Medical Center of the Rockies)LovelandColoradoAttivo, non in reclutamento
University of WisconsinMadisonWisconsinRitirato
UPMC Heart and Vascular InstituteMechanicsburgPennsylvaniaAttivo, non in reclutamento
Minneapolis HeartMinneapolisMinnesotaRitirato
St. Patrick HospitalMissoulaMontanaRitirato
Morristown Medical CenterMorristownNew JerseyRitirato
Intermountain Medical CenterMurrayUtahAttivo, non in reclutamento
Naples Community HospitalNaplesFloridaAttivo, non in reclutamento

Nella scheda del registro sono indicati altri 18 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

Non è stata registrata alcuna modifica da quando abbiamo acquisito questa scheda.

Viene registrata una modifica ogni volta che lo sponsor aggiorna la scheda del registro. Stato, date, arruolamento e centri compaiono qui man mano che cambiano.

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT04153292